TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB91983

Peptide_Name

vCPP 2319 vCPP2319

Activity

Antibacterial Anticancer Cell-penetrating Peptides Toxicity

Activity_category_statistics

Anti-infective peptides Cancer-related peptides Toxicity and safety peptides Delivery and barrier-penetrating peptides

Database_Source

AntiBP3 Peptipedia CancerPPD 2.0 CPPsite3.0

Sequence_Type

standard

Has_Modification No

Description A 20-aa standard natural multi-activity (Antibacterial, Anticancer, Cell-penetrating Peptides, and other sources) peptide sequence curated from AntiBP3, Peptipedia, CancerPPD 2.0, and other sources, with an available 3D structural model.

Modification

C-terminal: Amidation

Sequence

WRRRYRRWRRRRRWRRRPRR-NH2

FASTA

>TPDB91983|Antibacterial;Anticancer;Cell-penetrating Peptides;Toxicity|length=20
WRRRYRRWRRRRRWRRRPRR-NH2

Formula C137H228N68O22

Absent Amino Acids ANDCEQGHILKMFSTV

Common Amino Acids R

Mass 3179.76

PI 13.21

Basic Residues 15

Acidic Residues 0

Hydrophobic Residues 4

Net Charge +15

Boman Index 6.11

Hydrophobicity -3.655

Aliphatic Index 0.00

Half Life

Mammalian: 2.8 hour Yeast: 3 min E.coli: 2 min

Extinction Coefficient Cystines 17990

Absorbance 280nm 565.77

Polar Residues 1

number

0

A

15

R

0

N

0

D

0

C

0

E

0

Q

0

G

0

H

0

I

0

L

0

K

0

M

0

F

1

P

0

S

0

T

3

W

1

Y

0

V

Amino Acid Distribution

A: 0 R: 15 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 0 K: 0 M: 0 F: 0 P: 1 S: 0 T: 0 W: 3 Y: 1 V: 0

Length

20

Formula

C137H228N68O22

Mass

3179.76

PI

13.21

Net Charge

+15

Boman Index

6.11

Hydrophobicity

-3.655

C_terminal_Modification

Amidation

Chirality

L

Ionic_State

Cationic

Linear_or_Cyclic

Linear

Linearity

Linear

N_terminal_Modification

Free

Nature

Anticancer and Cell Penetrating

Origin

Capsid protein of the Torque teno douroucouli virus

SMILES

N[C@@H](CC1=CN=C(C)/C/1=C\C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CC1=CN=C(C)/C/1=C\C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)O N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)O

Evidence 1 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 4.5 ± 0.1 µM

Detail Source Activity Anticancer

Activity Measurement 4.5

Target

Cancer Type Breast Cancer

Cell Line MDA-MB-231

Tissue Affected Breast

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2022

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 4.2 ± 2.2 µM

Detail Source Activity Anticancer

Activity Measurement 4.2

Target

Cancer Type Breast Cancer

Cell Line BT-20

Tissue Affected Breast

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2022

Evidence 3 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 15.7 ± 1.5 µM

Detail Source Activity Anticancer

Activity Measurement 15.7

Target

Cancer Type Breast Cancer

Cell Line BT-474

Tissue Affected Breast

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2022

Evidence 4 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 14.0 ± 1.0 µM

Detail Source Activity Anticancer

Activity Measurement 14.0

Target

Cancer Type Breast Cancer

Cell Line SK-BR-3

Tissue Affected Breast

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2022

Evidence 5 Activity

Activity

Detail Source Activity Cell-penetrating Peptides

Target

Cell Line MDA-MB-231 And BT-20 Cells BT-474 And SKBR3 Cells MCF 10A And HS68 Cells

Source & Reference

Database Source CPPsite3.0

Source CPPsite3

Other

Source Activity Label	Source Definition
Cell-penetrating Peptides	CPPsite3.0 experimentally validated cell-penetrating peptide annotation.

CPP Category Natural residues Linear L Cationic

Source of Peptide Protein derived

Cargo Type CF-labelled at N terminal

Subcellular Localization Cytoplasm

Uptake Efficiency Internalization occurs in 15 min for MDA-MB-231 and MCF 10A cells.

In Vitro or In Vivo In vitro

DSSP Secondary Structure CCSGGGGTTTTGGGGCSTTC

Evidence 6 Activity

Activity

Detail Source Activity Cell-penetrating Peptides

Target

Cell Line Staphylococcus aureus (S. aureus) and MRSA, Escherichia coli (E. coli) and Pseudomonas aeruginosa (P. aeruginosa)

Source & Reference

Database Source CPPsite3.0

Source CPPsite3

Other

CPP Category Natural residues Linear L

Source of Peptide Protein derived

Uptake Mechanism Membrane distruption

In Vitro or In Vivo In vitro

DSSP Secondary Structure CCCGGGGCCSCCCCTTSSCC

DSSP_Secondary_Structure

CCSGGGGTTTTGGGGCSTTC CCCGGGGCCSCCCCTTSSCC